Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1–3a follicular lymphoma

Rie S. Bech(Aalborg University Hospital), Tarec Christoffer El‐Galaly(Aalborg University Hospital), Karen Dybkær(Aalborg University Hospital), Peter Brændstrup(Zealand University Hospital), Thomas Stauffer Larsen(Odense University Hospital), Line Stensig Lynggaard(Aarhus University Hospital), J.L. Brady, N. George Mikhaeel(Guy's and St Thomas' NHS Foundation Trust), Kasper Lindblad Nielsen(Aalborg University Hospital), Hans Erik Johnsen(Herlev Hospital), Martin Bøgsted(Chr. Hansen (Denmark)), Hiếu Nguyễn Trung(Herlev Hospital), Hans Bentzen(Aarhus University Hospital), Paw Jensen(Aalborg University Hospital)
British Journal of Haematology
May 23, 2017
10.1111/bjh.14775
Cited by 8

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma
|Blood|2009|390
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Leukemia|2012|362
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
|Leukemia|2015|256